Compare LEGH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGH | OMER |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.2M | 821.7M |
| IPO Year | 2018 | 2008 |
| Metric | LEGH | OMER |
|---|---|---|
| Price | $19.85 | $11.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $25.00 | ★ $32.50 |
| AVG Volume (30 Days) | 98.8K | ★ 714.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $164,567,000.00 | $29,868,000.00 |
| Revenue This Year | $11.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.29 | $2.95 |
| 52 Week High | $29.45 | $17.65 |
| Indicator | LEGH | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 43.34 | 44.69 |
| Support Level | $18.93 | $11.09 |
| Resistance Level | $22.69 | $11.90 |
| Average True Range (ATR) | 0.71 | 0.45 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 38.42 | 19.64 |
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.